CORRELATION BETWEEN SERUM PARATHYROID HORMONE LEVELS AND ARTERIAL STIFFNESS INDEX IN HEMODIALYSIS PATIENTS WITH CHRONIC RENAL FAILURE

Phúc Võ Hữu, Nghĩa Nguyễn Như, Đức Lê Thanh

Main Article Content

Abstract

Background: Hyperparathyroidism in patients with chronic renal failure undergoing periodic hemodialysis has been shown to increase vascular stiffness in several studies. However, data on the direct correlation between serum PTH levels and arterial stiffness index in this patient population remain inconsistent. Objectives: To evaluate the correlation between serum parathyroid hormone (PTH) levels and arterial stiffness index in patients with chronic renal failure (CRF) undergoing periodic hemodialysis. Materials and methods: A cross-sectional analytical study was conducted on 91 CRF patients undergoing MHD at Vinh Long General Hospital from June 2024 to March 2025. Results: The study population had an approximately equal male-to-female ratio, with a mean age of 49.92 ± 11.29 years. Most patients had hypertension (96.7%) and a body mass index (BMI) of <23 kg/m² (80.2%). The prevalence of dyslipidemia and smoking was 8.8% and 18.7%, respectively. The mean dialysis duration was 50.71 ± 50.63 months. The median serum PTH level was 48.8 pg/mL (Q1-Q3: 30.4–94.7). The mean brachial-ankle pulse wave velocity (baPWV) was 14.54 ± 2.91 m/s. A weak positive correlation (r = 0.23) was observed between serum PTH levels and baPWV, which was statistically significant (p = 0.029). Conclusion: This preliminary study indicates a weak positive correlation between serum PTH levels and arterial stiffness index in CRF patients undergoing periodic hemodialysis.

Article Details

References

1. Sipahioglu MH, Kucuk H, Unal A, et al. Impact of arterial stiffness on adverse cardiovascular outcomes and mortality in peritoneal dialysis patients. Perit Dial Int.2012; 32(1):73-80. Doi: 10.3747/pdi.2010.00186.
2. Shoji T, Emoto M, Shinohara K, et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol.2001;12(10):2117-2124. Doi: 10.1681/asn.V12102117.
3. Palit S, Kendrick J. Vascular calcification in chronic kidney disease: role of disordered mineral metabolism. Curr Pharm Des.2014;20(37):5829-33. Doi: 10.2174/1381612820666140212194926.
4. Bhuriya R, Li S, Chen SC, McCullough PA, Bakris GL. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis.2009;53(4 Suppl 4):S3-10. Doi: 10.1053/ j.ajkd.2008.11.029.
5. Kidney DIGO. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int.2024; 105(4s): S117-s314. Doi: 10.1016/j.kint.2023. 10.018.
6. Kato K, Nakashima A, Morishita M, Ohkido I, Yokoo T. Parathyroid hormone levels and pulse wave velocity in hemodialysis patients. Ther Apher Dial.2023;27(3): 552-561. Doi: 10.1111/ 1744-9987.13957.
7. Turgutkaya A, Aşçı G. The association between Hba1c and arterial stiffness among non-diabetic patients with chronic kidney disease. J Vasc Bras.2021;20:e20200245. Doi: 10.1590/1677-5449.200245.